The United States remains the world’s dominant life sciences market, supported by an ecosystem of 23,594 companies across biotechnology, medtech, digital health, pharma, investors, and supporting services. The 2026 United States Life Science Trend Analysis, produced in partnership with BioFlorida, the State of Maryland, Ohio Life Sciences, and Salt Lake City, highlights an industry defined by prolific innovation, deep capital markets, and unmatched commercialization capacity.
The ecosystem includes 9,109 biotech companies, 2,965 medtech firms, 2,322 digital health companies, and 3,229 investors. Biotech activity spans therapeutics & diagnostics, R&D services, and other biotech, with oncology, neurology, and infectiology/parasitology among the most active clinical indications. Clinical development reflects a broad pipeline across all stages, with 16,509 therapeutic assets available for out-licensing.
Financing activity underscores the market’s global leadership. The top five private equity rounds in 2025 alone exceeded $2B, led by Kailera Therapeutics ($600M) and MapLight Therapeutics ($372.5M), while M&A deal values ranged from $3.9B to $14.6B. IPO markets remained active, with the largest 2025 listing raising $693M.
Looking ahead, the U.S. life sciences sector is well positioned for continued growth, underpinned by a deep early-stage pipeline, sustained investor appetite, and strong deal activity across licensing, partnerships, and M&A.
For more detailed insights, request a free Biotechgate demo.
Download the USA Trend Analysis Report for 2026